A Case of Cerebral Venous Thrombosis in a Patient with Graves’ Disease

Bo Ra Kim¹, Jung Hwa Jung¹, Jong Ryeal Hahn¹,², Jaehoon Jung¹,², Hee Jung Park¹, Soo Kyoung Kim¹,²

¹Department of Internal Medicine, Gyeongsang National University School of Medicine, Jinju, Gyeongsangnam-do, Korea
²Gyeongsang Institute of Health Science, Gyeongsang National University School of Medicine, Jinju, Gyeongsangnam-do, Korea

Superior sagittal sinus thrombosis is an uncommon disease, and 25% of cases are considered to be idiopathic. Hypercoagulability, local bloodstream stasis, and vessel wall abnormalities may contribute to the development of this condition. The thyrotoxic phase of Graves’ disease is associated with venous thrombosis caused by hypercoagulability, which is in turn induced by increased levels of homocysteine and factor VIII and decreased fibrinolytic activity. Here, we report the case of a 39-year-old male who presented with superior sagittal sinus thrombosis and concomitant hyperthyroidism.

Key Words: Cerebral venous thrombosis, Thyrotoxicosis, Protein C Deficiency

Cerebral vein thrombosis (CVT) is an uncommon disease and known risk factors of CVT are hereditary thrombophilia, pregnancy, puerperium, and use of oral contraceptives.¹ However, 25% of all cases are considered to be idiopathic.² Thyrotoxicosis may be a predisposing factor of CVT due to a hypercoagulable state.³⁴ Possible associations between thyrotoxicosis and CVT have been described in several case reports.⁵⁻⁸ Here, we report a case of CVT in a patient with Graves’ disease.

CASE

A 39-year-old male presented to the emergency room with generalized tonic-clonic seizure and right hemiplegia. He had no history of seizures or cerebrovascular disease, and his medical history was unremarkable except for Graves’ disease, for which he had been treated with methimazole for 1 year prior to admission. Recently, his thyrotoxic state had become aggravated and his methimazole dose was increased to 7.5mg per day 2 weeks prior (from 2.5mg per day). His vital signs were stable except for sinus tachycardia (110 beats/min), and he complained of palpitation. He exhibited mild thyroid enlargement and mild Graves’ ophthalmopathy.
Laboratory tests confirmed a thyrotoxic status: free T4, 4.01 ng/dL (normal 0.93-1.70 ng/dL); tri-iodothyronine 271 ng/dL (normal 80-200 ng/dL); TSH, below 0.01 mIU/L (normal 0.27-4.2 mIU/L); and thyroid-stimulating antibody, 40 IU/L (normal 0-1.75 IU/L).

Hematological and coagulation tests showed that platelet counts, prothrombin time, partial thromboplastin time, and the levels of antithrombin III and coagulation factor VIII were within normal ranges. The factor V Leyden mutation was absent, and lupus anticoagulant, anti-cardiolipin antibodies, and anti-phospholipid antibodies were absent. However, the level of protein C (24%, normal 72-160%) and protein S (55%, normal 60-150%) were low. Abnormal serum glucose and electrolyte value was not detected.

Electrocardiography revealed sinus tachycardia and echocardiography showed normal left ventricular size and function with no evidence of an intra-cardiac thrombus. The electroencephalogram was normal.

Brain magnetic resonance imaging (MRI) revealed hyperintensity associated with thrombosis within the superior sagittal sinus (Fig. 1); this was confirmed by brain computed tomography angiography (Fig. 2).

The patient was admitted to our intensive care unit, and treatment with intravenous heparin and methimazole 7.5 mg/day was commenced. After 3 days, his clinical condition gradually improved. The focal neurological deficits disappeared after

![Image](image-url)

**Fig. 1.** Fluid-attenuated inversion recovery (FLAIR, A) and diffusion-weighted MR images (DWI, B) demonstrate multiple hyperintense lesions in both high frontal cortices (arrows). The lesions are more clearly demonstrated on DWI (B) than on FLAIR image (A).
several days of treatment, and his consciousness became normalized. He was treated with methimazole 7.5 mg/day and an oral anticoagulant to obtain an INR (International Normalized Ratio) between 2 and 3. Six months after discharge, the patient has been doing well. He exhibits complete neurological recovery and has maintained normal thyroid function with methimazole.

DISCUSSION

CVT is very uncommon condition and it’s mortality rate is about 5%. Instances of CVT in Graves’ disease patients are also rare. Several previous studies suggested that hyperthyroidism is associated with increased risk of arterial and venous thromboembolism. Observation from several case reports have shown the increased risk of CVT or pulmonary thromboembolism in patients with hyperthyroidism. Rau et al. reported a case of Graves’ disease with CVT presented with headache and general weakness in old man. He exhibited a high level of fibrinogen, low protein C activity, and atrial fibrillation. Verberne et al. reported the case of Graves’ disease with CVT presenting as a viral encephalitis in young woman through a factor VIII-medicated

![Fig. 2. Brain computed tomography (CT) angiography shows segmental 2 occlusion of the superior sagittal sinus due to thrombosis (arrows).](image-url)
hypercoagulability. Grien et al. reported two case of Graves’ disease complicated by pulmonary embolism. Of these patients, young woman showed the increased level of coagulation factor VIII.14

Systemic literature review reported that the most frequently involved sites was cerebral venous veins, and over 60% of these cases reported the additional thrombophilic risk factor such as factor V Leiden mutation or protein C deficiency.10

Although the precise mechanism underlying CVT or other thromboembolic events in Graves’ disease remains unclear, several possibilities have been suggested. These include hypercoagulation, venous stasis, and abnormalities of the venous walls.4,15,16 Many abnormalities of blood coagulation during thyrotoxic state have been described. The patient with hyperthyroidism had the shorten activated partial thrombo-plastin time, higher fibrinogen levels, increased levels of factor VIII and homocysteine, and decreased fibrinolytic activity during thyrotoxicosis in the previous studies.5-7,16 Increased fibrinogen levels and reduced levels of protein C were also associated with CVT development in Graves’ disease patients.6 The factor V Leiden mutation has been found in another case of thyrotoxic patient with CVT.17 Our case also showed a reduced protein C and protein S level. Protein C inhibits coagulation by inactivating factors VIIIa and Va. Patients with protein C deficiency may be at increased risk of thrombo-embolic events.6 Apart from such changes in the coagulation system, several inherited or acquired risk factors for thrombosis are known in thyrotoxic patients.11 Thyrotoxic state could induce vascular endothelial dysfunction,11 and venous stasis caused by goiter could affect CVT development.5 In our case, except for protein C and protein S deficiency, other thrombophilic features were normal and no other risk factor for venous thrombosis was identified. Furthermore, the goiter was not large that could trigger venous stasis. Overt hyperthyroidism is associated with thromboembolic events through several mechanisms evidenced by several case series. Therefore, CVT should be suspected in thyrotoxic patients with neurological symptoms. In addition, such patients should be screened for any accompanying underlying coagulopathy. Future large observational study is needed to provide the more information about the association between hyperthyroidism and coagulation-fibrinolytic abnormalities.

REFERENCES

4. Erem C, Ersoz HO, Karti SS, Ukin; K, Hacihasanoglu


